Tag: AstraZeneca

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), PepGen, Inc. (NASDAQ: PEPG), and Tempus AI, Inc. (NASDAQ: TEM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Unites Pharma Marketing, PR & Communications, New Product Planning & Commercialization, and Medical Affairs Communities; Thought Leaders from AbbVie, AstraZeneca, BMS, GSK, Johnson & Johnson, NBCUniversal, Pfizer, Takeda and More Deliver Unparalleled Education

SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

NEW YORK and NEW ORLEANS, June 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)  (NASDAQ: TEM) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

mRNA Market Surges: The global mRNA market is booming, fueled by the success of COVID-19 vaccines, with applications expanding to cancer and genetic disorders. Driven by public-private investments, the industry sees pharmaceutical giants like Pfizer and Moderna spearheading innovations. Despite challenges such as high costs, the market is set for substantial growth through 2035, with North America leading due to its robust healthcare infrastructure. Recent collaborations, such as Etherna Immunotherapies with Dropshot Therapeutics, are further accelerating RNA therapeutic developments.